Back

Anticoagulation profile of high-dose vs. standard-dose enoxaparin for percutaneous coronary intervention

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Interventional Cardiology ePosters Adjunctive Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Qian Chen

Peking Union Medical College Hospital, Beijing (China)

174 More presentations in this session

Presentation thumbnail
Clinical profile and predictors of positivity of acetylcholine test in patients with angina and no obstructive coronary artery disease. Results of a multi-center mediterranean registry.
Doctor L. Grigorian (Madrid, ES)
Abstract Slides
Presentation thumbnail
Comparison of neointimal coverage between biodegradable-polymer everolimus-eluting stent and durable-polymer everolimus-eluting stent using angioscopy for the patients with acute coronary syndrome
Assistant Professor T. Umemoto (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Global risk factors of contrast-Induced acute kidney injury: systematic review and meta-analysis
Doctor L. Liu (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Post-procedural quantitative flow ratio gradient and target lesion revascularization after drug-coated balloon or plain-old balloon angioplasty
Doctor H. Kirigaya (Yokohama, JP)
Abstract Slides
Presentation thumbnail
Hyperemic hemodynamic characteristics of serial coronary lesions assessed by pressure pullbacks gradients (PPG) index.
Doctor A. Candreva (Zurich, CH)
Abstract Slides

Access the full session

Session thumbnail
Interventional Cardiology ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
A patient with recent non-ST elevation myocardial infarction and percutaneous coronary intervention requiring cancer surgery: what do the guidelines say?
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
thumbnail
Congress Session
Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources